Cardiology Research Review: Issue 151, with commentary by A/Prof John Amerena.

In this edition:

–  Smartwatch-enabled detection of LV dysfunction
–  Dapagliflozin in patients with HF with improved ejection fraction
–  Empagliflozin in HF patients with preserved vs mid-range ejection fraction
–  Trends and real-world safety of PCI for stable ischaemic heart disease
–  Low-dose rosuvastatin vs dietary supplements
–  Reanalysis of mortality data from the FOURIER trial
–  Effects of olpasiran on lipoprotein(a) levels in patients with ASCVD
–  Screening for risk of sudden cardiac death in young competitive athletes
–  Baxdrostat for treatment-resistant hypertension
–  Major cardiovascular events and subsequent risk of kidney failure requiring replacement therapy

Download Cardiology_Research_Review_Issue_151 (pdf), with commentary by A/Prof John Amerena.